Soufflé Therapeutics

Soufflé Therapeutics is a Watertown, Massachusetts-based biotechnology company founded by pioneers in genetic medicine including MIT professors Robert Langer and Daniel Anderson, along with Victor Kotelianski and Marino Zerial. The company engineers cell-specific ligands to deliver siRNA-based medicines that are precise, potent, and transferred across the cell membrane to their target. Soufflé combines proprietary technologies for cell-specific receptor identification, ligand optimization, and siRNA engineering to create safer, stronger, and more durable medicines. Its first programs target Facioscapulohumeral Muscular Dystrophy (FSHD) and genetically-driven cardiomyopathies, with clinical trials planned for 2026. The company emerged from stealth in October 2025 with $200M in Series A financing and has executed over $3.5B in capital raised and collaboration agreements with pharma partners including Bayer, AbbVie, Amgen, and Novo Nordisk.